secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-067978
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Codexis appoints Cynthia Collins to Board of Directors as Class II director
---------------------------------------------------------------------------

- Appointed effective March 28, 2025 as Class II director; term expires at 2027 annual meeting.
- Board determined Collins is independent under Nasdaq rules; appointed to Compensation Committee.
- Previously CEO of Editas Medicine (2019-2021); currently Executive Chair/Interim CEO of Nutcracker Therapeutics.
- Receives $50k annual cash retainer plus $20k for committee; initial RSU grant of ~$200k vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000119312525067978/0001193125-25-067978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000119312525067978/d915487d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-067978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer